Press release
Dyskinesia Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Dyskinesia Overview
Dyskinesia is a movement disorder that often appears as uncontrolled shakes, tics, or tremors. Often, the condition occur in people with Parkinson's disease due to the overstimulation of their dopamine receptors from medications that increase this neurotransmitter in the brain
"Dyskinesia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dyskinesia Market.
The Dyskinesia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Dyskinesia Pipeline Report: https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dyskinesia treatment therapies with a considerable amount of success over the years. Dyskinesia Key players such as - Contera Pharma, PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others, are developing therapies for the Dyskinesia treatment
• Dyskinesia Emerging therapies such as - CP 011, PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others are expected to have a significant impact on the Dyskinesia market in the coming years.
• In February 2020, Bukwang received the investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with phase II clinical study of JM-010. JM-010, originating from a Danish bioventure company Contera Pharma, is currently under development for treating dyskinesia which emerges in up to90% of Parkinson's disease patients following long term treatment of levodopa
Route of Administration
Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Dyskinesia Pipeline Therapeutics Assessment
• Dyskinesia Assessment by Product Type
• Dyskinesia By Stage and Product Type
• Dyskinesia Assessment by Route of Administration
• Dyskinesia By Stage and Route of Administration
• Dyskinesia Assessment by Molecule Type
• Dyskinesia by Stage and Molecule Type
DelveInsight's Dyskinesia Report covers around products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Some of the key companies in the Dyskinesia Therapeutics Market include:
Key companies developing therapies for the Dyskinesia treatment are - Auspex Pharmaceuticals, Neurocrine Biosciences Inc., Synchroneuron Inc., Teva Pharmaceutical Industries Ltd., and others.
Emerging Dyskinesia Drugs Under Different Phases of Clinical Development Include:
• CP 011: Contera Pharma
• PCT-3012: PolyCore Therapeutics
• Mesocarb: Melior Pharmaceuticals
• ML 007: MapLight Therapeutics
• LY 03015: Luye Pharma Group
• JM-010 : Contera Pharma
• NLX 112: Neurolixis
• CPL 500036: Celon Pharma
• JM-010: Contera Pharma
• NLX 112: Neurolixis
• CPL 500036: Celon Pharma
Get a Free Sample PDF Report to know more about Dyskinesia Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Dyskinesia Pipeline Analysis:
The Dyskinesia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dyskinesia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dyskinesia Treatment.
• Dyskinesia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dyskinesia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dyskinesia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Dyskinesia product details are provided in the report. Download the Dyskinesia pipeline report to learn more about the emerging Dyskinesia therapies at:
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Dyskinesia Pipeline Market Drivers
• Increase in prevalence of Dyskinesia
• Increase in the demand for disease specific novel treatment
Dyskinesia Pipeline Market Barriers
• Lack of understanding of the pharmacology of Dyskinesia
• Side-effects associated with drugs
Scope of Dyskinesia Pipeline Drug Insight
• Coverage: Global
• Key Dyskinesia Companies: Contera Pharma, PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others
• Key Dyskinesia Therapies: CP 011, PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others
• Dyskinesia Therapeutic Assessment: Dyskinesia current marketed and Dyskinesia emerging therapies
• Dyskinesia Market Dynamics: Dyskinesia market drivers and Dyskinesia market barriers
Request for Sample PDF Report for Dyskinesia Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Dyskinesia Report Introduction
2 Dyskinesia Executive Summary
3 Dyskinesia Overview
4 Dyskinesia- Analytical Perspective In-depth Commercial Assessment
5 Dyskinesia Pipeline Therapeutics
6 Dyskinesia Late Stage Products (Phase II/III)
7 Dyskinesia Mid Stage Products (Phase II)
8 Dyskinesia Early Stage Products (Phase I)
9 Dyskinesia Preclinical Stage Products
10 Dyskinesia Therapeutics Assessment
11 Dyskinesia Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Dyskinesia Key Companies
14 Dyskinesia Key Products
15 Dyskinesia Unmet Needs
16 Dyskinesia Market Drivers and Barriers
17 Dyskinesia Future Perspectives and Conclusion
18 Dyskinesia Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Dyskinesia drugs and therapies- https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports
Dyskinesia Market https://www.delveinsight.com/report-store/dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dyskinesia-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Dyskinesia Epidemiology https://www.delveinsight.com/report-store/dyskinesia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dyskinesia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dyskinesia Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2938778 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Dyskinesia
Dyskinesia Market Emerging Trends and Growth Prospects 2034
Introduction
Dyskinesia, characterized by involuntary and uncontrolled movements, often arises as a side effect of long-term dopaminergic treatment in neurological disorders such as Parkinson's disease. As global cases of movement disorders continue to climb, so too does the need for therapies that effectively manage dyskinesia while preserving quality of life. The dyskinesia market has emerged as a critical segment of the wider central nervous system (CNS) therapeutics industry, shaped by aging…
Tardive Dyskinesia Market Report and Forecast 2024-2032
The tardive dyskinesia market size is anticipated to grow at a CAGR of 3.2 % during the forecast period of 2024-2032, driven by growing awareness about the importance of monitoring patients on long-term antipsychotic therapy for early signs of tardive dyskinesia in the major markets.
Tardive Dyskinesia: Introduction
Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive body movements. It primarily affects the face, causing grimacing, blinking, or lip-smacking, but can…
Dyskinesia Pipeline involves 40+ key companies continuously working towards deve …
"DelveInsight's Dyskinesia Pipeline Insight 2022 report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in the Dyskinesia pipeline landscape"
It covers the Dyskinesia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dyskinesia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Dyskinesia Pipeline Report
• DelveInsight's Dyskinesia Pipeline…
Primary Ciliary Dyskinesia Pipeline: Insights into Novel Key Pharma Companies, G …
DelveInsight's, "Primary Ciliary Dyskinesia Pipeline Insight, 2022," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In the Primary Ciliary Dyskinesia Pipeline Report, detailed…
Tardive Dyskinesia Therapeutics- Pipeline Analysis 2018, Clinical Trials & Resul …
Tardive dyskinesia (TD) is an involuntary neurological movement disorder caused by the use of dopamine receptor blocking drugs which are prescribed to treat certain psychiatric or gastrointestinal conditions. Long-term use of these drugs may produce biochemical abnormalities in the area of the brain known as the striatum.
Download the sample report @ https://www.pharmaproff.com/request-sample/1106
The reasons that some people who take these drugs may get TD, and some people do not, is…
Tardive Dyskinesia Drugs Market
Tardive dyskinesia (TD) is a form of dyskinesia that is difficult to treat. It is a nerve disorder characterized by involuntary movements such as jaw, lips, and tongue, considered as grimacing, sticking the tongue out, and lip smacking. Some other symptoms are an individual experiencing involuntary movement of the lower and upper extremities and also breathing choking. According to Center for Drug Evaluation and Research, tardive dyskinesia can lead to…
